Phase II study alternating mFOLFOX 6 and FOLFIRI (FIREFOX) plus bevacizumab (bev) regimen in first-line treatment of advanced colorectal cancer in Japanese patients (KSCC 0801).

被引：0
|
作者：
Ogata, Yutaka
Akagi, Yoshito
Kakeji, Yoshihiro
Emi, Yasunori
Oki, Eiji
Saeki, Hiroshi
Touyama, Tetsuo
Samura, Hironori
Baba, Hideo
Natsugoe, Shoji
Shirouzu, Kazuo
Tokunaga, Shoji
Maehara, Yoshihiko
机构：
[1] Kurume Univ, Dept Surg, Kurume Med Ctr, Sch Med, Kurume, Fukuoka, Japan
[2] Kurume Univ, Dept Surg, Sch Med, Kurume, Fukuoka, Japan
[3] Kyushu Univ, Dept Surg & Sci, Fukuoka, Japan
[4] Nakagami Hosp, Okinawa, Japan
[5] Univ Ryukyus, Dept Surg 1, Nishihara, Okinawa, Japan
[6] Kumamoto Univ, Dept Surg Gastroenterol, Kumamoto, Japan
[7] Kagashima Univ, Dept Gastrointestinal Surg, Kagoshima, Japan
[8] Kyushu Univ Hosp, Med Informat Ctr, Fukuoka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 04期
关键词：
D O I：
10.1200/jco.2012.30.4_suppl.602
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
602
引用
收藏
页数：2
相关论文
共 50 条
  • [1] PHASE II STUDY ALTERNATING MFOLFOX 6 AND FOLFIRI (FIREFOX) PLUS BEVACIZUMAB (BEV) REGIMEN IN FIRST-LINE TREATMENT OF ADVANCED COLORECTAL CANCER IN JAPANESE PATIENTS (KSCC 0801)
    Emi, Y.
    Ogata, Y.
    Akagi, Y.
    Kakeji, Y.
    Oki, E.
    Saeki, H.
    Shimokawa, M.
    Touyama, T.
    Samura, H.
    Baba, H.
    Natsugoe, S.
    Shirouzu, K.
    Tokunaga, S.
    Maehara, Y.
    ANNALS OF ONCOLOGY, 2012, 23 : 130 - 130
  • [2] Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801)
    Keisuke Miwa
    Eiji Oki
    Yasunori Emi
    Hiroshi Saeki
    Tetsuya Kusumoto
    Yoshito Akagi
    Yutaka Ogata
    Hironori Samura
    Shoji Tokunaga
    Hiroshi Ishikawa
    Takaho Tanaka
    Susumu Sueyoshi
    Hidefumi Higashi
    Hiroyuki Matsuda
    Tetsuo Touyama
    Yoshihiko Maehara
    International Journal of Clinical Oncology, 2016, 21 : 110 - 117
  • [3] Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801)
    Miwa, Keisuke
    Oki, Eiji
    Emi, Yasunori
    Saeki, Hiroshi
    Kusumoto, Tetsuya
    Akagi, Yoshito
    Ogata, Yutaka
    Samura, Hironori
    Tokunaga, Shoji
    Ishikawa, Hiroshi
    Tanaka, Takaho
    Sueyoshi, Susumu
    Higashi, Hidefumi
    Matsuda, Hiroyuki
    Touyama, Tetsuo
    Maehara, Yoshihiko
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2016, 21 (01) : 110 - 117
  • [4] Phase II trial alternating mFOLFOX 6 and FOLFIRI (FIREFOX) regimens in first-line treatment of advanced colorectal cancer in Japanese patients (KSCC 0701).
    Akagi, Y.
    Tokunaga, S.
    Emi, Y.
    Kakeji, Y.
    Kusumoto, T.
    Baba, H.
    Ogata, Y.
    Tanaka, T.
    Shirouzu, K.
    Maehara, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] A Phase II Clinical Study of mFOLFOX6 Plus Bevacizumab as First-line Therapy for Japanese Advanced/Recurrent Colorectal Cancer Patients
    Nishina, Tomohiro
    Takano, Yoshinao
    Denda, Tadamichi
    Yasui, Hisateru
    Takeda, Koji
    Ura, Takashi
    Esaki, Taito
    Okuyama, Yusuke
    Kondo, Ken
    Takahashi, Yasuo
    Sugiyama, Yasuyuki
    Muro, Kei
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (11) : 1080 - 1086
  • [6] Phase II Trial of Alternating mFOLFOX6 and FOLFIRI Regimens in the First-Line Treatment for Unresectable or Metastatic Colorectal Cancer (KSCC0701)
    Oki, Eiji
    Emi, Yasunori
    Akagi, Yoshito
    Tokunaga, Shoji
    Sadanaga, Noriaki
    Tanaka, Takaho
    Ogata, Yutaka
    Saeki, Hiroshi
    Kakeji, Yoshihiro
    Baba, Hideo
    Nishimaki, Tadashi
    Natsugoe, Shoji
    Shirouzu, Kazuo
    Maehara, Yoshihiko
    ONCOLOGY, 2013, 84 (04) : 233 - 239
  • [7] Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)
    Yamazaki, K.
    Nagase, M.
    Tamagawa, H.
    Ueda, S.
    Tamura, T.
    Murata, K.
    Nakajima, T. Eguchi
    Baba, E.
    Tsuda, M.
    Moriwaki, T.
    Esaki, T.
    Tsuji, Y.
    Muro, K.
    Taira, K.
    Denda, T.
    Funai, S.
    Shinozaki, K.
    Yamashita, H.
    Sugimoto, N.
    Okuno, T.
    Nishina, T.
    Umeki, M.
    Kurimoto, T.
    Takayama, T.
    Tsuji, A.
    Yoshida, M.
    Hosokawa, A.
    Shibata, Y.
    Suyama, K.
    Okabe, M.
    Suzuki, K.
    Seki, N.
    Kawakami, K.
    Sato, M.
    Fujikawa, K.
    Hirashima, T.
    Shimura, T.
    Taku, K.
    Otsuji, T.
    Tamura, F.
    Shinozaki, E.
    Nakashima, K.
    Hara, H.
    Tsushima, T.
    Ando, M.
    Morita, S.
    Boku, N.
    Hyodo, I.
    ANNALS OF ONCOLOGY, 2016, 27 (08) : 1539 - 1546
  • [8] PHASE II TRIAL OF BIWEEKLY ALTERNATING FOLFOX AND FOLFIRI REGIMEN AS FIRST-LINE TREATMENT IN ADVANCED COLORECTAL CANCER (ACC)
    Bernardo, G.
    Palumbo, R.
    Bernardo, A.
    Villani, G.
    Poggi, G.
    Frascaroli, M.
    Jedrychowska, I.
    Delmonte, A.
    Teragni, C.
    Strada, M. R.
    ANNALS OF ONCOLOGY, 2004, 15 : 59 - 59
  • [9] A phase II trial of alternating mXELOX/mXELIRI plus bevacizumab (BEV) as first-line treatment for metastatic colorectal cancer (mCRC)
    Li, Sheng
    Zhu, Liangjun
    Li, Xiaoyou
    Huang, Jiayuan
    Xu, Hanfeng
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study
    Kochi, Mitsugu
    Akiyama, Yuji
    Aoki, Tatsuya
    Hagiwara, Ken
    Takahashi, Takao
    Hironaka, Katsuji
    Teranishi, Futoshi
    Osuka, Fumihiko
    Takeuchi, Masahiro
    Fujii, Masashi
    Nakajima, Toshifusa
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (05) : 1097 - 1102
12345